The pro-inflammatory cytokine tumor necrosis factor alpha (TNF-1) regulates cell differentiation and apoptosis in the immune system. However, TNF-1 and its receptors are also found in the central nervous system. Increased levels of TNF-1 have been implicated in depression and anxiety. However, it is unclear whether ambient/physiological levels of TNF-1 (in the absence of pathological inflammation) play a role in anxiety and depression or other neuropsychiatric disease. Our laboratory has recently found that TNF-1 knockout (KO) mice display reduced avoidance of fearful and increased exploration of novel environments, behaviors consistent with reduced anxiety- like behavior. Genetic inactivation of other factors implicated in anxiety such as the 5- HT transporter, 5-HT1A receptor and brain derived neurotrophic factor (BDNF) in contrast results in an anxiogenic-like effect. These data suggest that anxiety levels are bi- directionally modulated by genes and that increased or decreased anxiety could be the result of an imbalance between these or similar gene effects. In searching for a neuronal mechanism that could be associated with the expression of specific manifestations of anxiety (avoidance and exploration of a novel and fear inducing environment), we identified proliferation of neuronal precursors during early postnatal life as a potential contributing factor. Indeed proliferation and the level of anxiety were inversely correlated in TNF KO mice.
The aims of this application are to specify the cell source of TNF (aim 1), the developmental time of TNF's action (aim 2) and the neuronal and molecular mechanisms of TNF-mediated regulation of proliferation and anxiety levels (aim 3). An additional goal is to causally link postnatal neuronal precursor proliferation to specific manifestations of anxiety using genetic and pharmacological rescue strategies (aim 4).

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH080194-04
Application #
8002009
Study Section
Special Emphasis Panel (ZRG1-BDCN-A (90))
Program Officer
Panchision, David M
Project Start
2008-02-15
Project End
2012-11-30
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
4
Fiscal Year
2011
Total Cost
$374,220
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Zupan, Bojana; Liu, Bingfang; Taki, Faten et al. (2017) Maternal Brain TNF-? Programs Innate Fear in the Offspring. Curr Biol 27:3859-3863.e3
Toth, Miklos (2015) Mechanisms of non-genetic inheritance and psychiatric disorders. Neuropsychopharmacology 40:129-40
Liu, Bingfang; Zupan, Bojana; Laird, Emma et al. (2014) Maternal hematopoietic TNF, via milk chemokines, programs hippocampal development and memory. Nat Neurosci 17:97-105
Gleason, Georgia; Zupan, Bojana; Toth, Miklos (2011) Maternal genetic mutations as gestational and early life influences in producing psychiatric disease-like phenotypes in mice. Front Psychiatry 2:25
Yee, Karen K; Pribitkin, Edmund A; Cowart, Beverly J et al. (2010) Neuropathology of the olfactory mucosa in chronic rhinosinusitis. Am J Rhinol Allergy 24:110-20
Borgmann-Winter, K E; Rawson, N E; Wang, H-Y et al. (2009) Human olfactory epithelial cells generated in vitro express diverse neuronal characteristics. Neuroscience 158:642-53
Yee, Karen K; Pribitkin, Edmund A; Cowart, Beverly J et al. (2009) Smoking-associated squamous metaplasia in olfactory mucosa of patients with chronic rhinosinusitis. Toxicol Pathol 37:594-8
Sun, Yuhua; Zupan, Bojana; Raaka, Bruce M et al. (2009) TRH-receptor-type-2-deficient mice are euthyroid and exhibit increased depression and reduced anxiety phenotypes. Neuropsychopharmacology 34:1601-8
Turetsky, Bruce I; Hahn, Chang-Gyu; Borgmann-Winter, Karin et al. (2009) Scents and nonsense: olfactory dysfunction in schizophrenia. Schizophr Bull 35:1117-31
Zupan, Bojana; Toth, Miklos (2008) Wild-type male offspring of fmr-1+/- mothers exhibit characteristics of the fragile X phenotype. Neuropsychopharmacology 33:2667-75